Alnylam Pharmaceuticals is seeing increased interest from investment banks, evident from multiple price targets being raised, with Goldman Sachs setting the highest at
$566.00. It joined the
Alliance for Genomic Discovery, hinting at an expansion into precision medicine. In recent corporate developments, Alnylam has experienced both rises and falls. Its Phase 1 Study of ALN-AGT01 RVR successfully concluded, and it settled patent lawsuits with Moderna over COVID vaccine technology. On the negative side, the company's RNAi drug failed in a trial, but plans for Phase 3 are ongoing. Lots of movement has been seen on the stock front as a multitude of companies made new investments in or increased their holdings of Alnylam, including Sumitomo Mitsui DS Asset Management and Swedbank AB, among many others. In contrast, Pallas Capital Advisors and Gateway Investment Advisers decreased their holdings. Finally, news of the company finally obtaining
FDA approval for AMVUTTRA, an RNAi therapeutic for ATTR Amyloidosis with Cardiomyopathy, has invigorated the outlook for Alnylam's stock.
Alnylam Pharmaceuticals News Analytics from Thu, 20 Mar 2025 07:00:00 GMT to Sat, 20 Sep 2025 18:28:12 GMT -
Rating 8
- Innovation 7
- Information 6
- Rumor -2
